By Sheeba M. | Weedstock Market Intelligence | Monday, September 28, 2026 — 2:00 PM ET
Cannabis equities opened the final trading week of September with renewed momentum Monday as institutional flows accelerated into the DEA Final-4 countdown — the market’s shorthand for the four remaining business days before the anticipated October 2, 2026 DEA scheduling announcement window. Pre-market volume across major multi-state operators (MSOs) ran 30–45% above the 30-day average, signaling that capital positioning is no longer tentative.
Monday Morning Stock Snapshot
Curaleaf Holdings (CURLF) led pre-market activity, extending Friday’s close with a 3.8% gap up on volume of 2.1M shares in the first 90 minutes. The stock’s 14-day RSI has crossed back above 55, a level technicians watch as confirmation of trend resumption after the mid-September consolidation. Analysts tracking the Q3 2026 earnings cycle note that Curaleaf’s Florida and New York footprint positions the company to be among the first MSOs to report material Schedule III benefit if rescheduling proceeds as anticipated.
Green Thumb Industries (GTBIF) opened flat before recovering to a 1.9% gain by 10:30 AM ET. Illinois remains GTI’s core revenue anchor, and Friday’s state-level dispensary traffic data — released by IDFPR — showed a 6.2% week-over-week increase in adult-use sales. GTI’s operational leverage in its home market continues to be a differentiated thesis heading into the October catalyst window.
Verano Holdings (VRNOF) added 2.4% on moderate volume, with options activity suggesting renewed call positioning in the $7–$9 strike range for October expiration. Verano’s multi-state diversification story — spanning 14 states including strategically important Pennsylvania and New Jersey — makes it a favored volatility play for traders expecting a binary outcome from the DEA announcement.
Canopy Growth (CGC) and Tilray Brands (TLRY) both traded in range, with CGC up 1.1% and TLRY flat. Canadian LP stocks tend to lag U.S. MSOs in DEA-driven rallies given the distinct regulatory pathway, though both companies have meaningful U.S. hemp and CBD exposure that provides partial participation in the sector’s upside momentum.
Why Monday’s Open Matters
The final week of September carries outsized significance for cannabis investors in 2026 because it overlaps with three converging catalysts:
- DEA October Window: The Drug Enforcement Administration’s rescheduling review process — which would move cannabis from Schedule I to Schedule III under the Controlled Substances Act — is widely expected to reach a public comment period conclusion or an administrative law judge decision by early October. The cannabis sector‘s 280E tax burden, estimated at $500M–$800M annually across publicly traded MSOs, hangs on this outcome.
- Q3 2026 Earnings Runway: Companies begin reporting Q3 results in mid-October, meaning current positioning reflects both the regulatory catalyst and expectations for operational performance. Analysts at multiple coverage shops have raised EPS estimates for CURLF and GTBIF based on improving same-store sales trends through August.
- End-of-Quarter Rebalancing: Institutional funds approaching September 30 quarter-end may be adjusting cannabis allocations, adding technical buying pressure that can amplify price moves in either direction.
Market Intelligence Takeaway
Monday’s open confirms that institutional money has not vacated the cannabis trade. The DEA Final-4 framework implies that each remaining trading day of September carries elevated event-risk. Traders with short-term horizons are advised to monitor options flow for signals on consensus direction, while longer-term investors may view current levels in CURLF and GTBIF as the final accumulation window before the October catalyst plays out.
Track live cannabis stock movements at the Weedstock stock tracker. This article is for informational purposes only and does not constitute financial advice.